Contact: Alexander Shtifman
Phone: 617-713-8989
alex...@childrens.harvard.edu

Text adapted from the Leukemia & Lymphoma Society press release

The Leukemia & Lymphoma Society (LLS) announced it has awarded one of two new Marshall A. Lichtman Specialized Center of Research (SCOR) grants to Frederick W. Alt, Ph.D.  He is the Charles A. Janeway Professor of Pediatrics and Professor of Genetics at Harvard Medical School, and the Director and President of the Program of Cellular and Molecular Medicine and the Immune Disease Institute (PCMM/IDI).  Each SCOR is valued at $1.25 million a year for five years for a total of $6.25 million.

The SCOR program is LLS's largest academic research grant, with total funding of more than $235 million since its inception in 2000.  The SCOR program brings together teams of researchers representing different disciplines in collaborative efforts to discover new approaches to treat patients with leukemia, lymphoma and myeloma.  Awards go to groups that best demonstrate outstanding scientific promise facilitated by the synergy that will occur from their combined efforts.

Alt's project title is "Pathogenetic Mechanisms and Therapeutic Targets in B-Cell Lymphoma," and his team's goal is to learn more about the specific ways B cell lymphomas develop and to create new targeted therapies to eliminate these malignant cells.  The team members are Margaret Shipp, M.D., Glenn Dranoff, M.D. and Loren Walensky M.D., Ph.D., all from the Dana Farber Cancer Institute, and Scott Rodig, M.D., Ph.D., from Brigham and Women's Hospital.  They are investigating both mouse lymphoma models and clinical samples from lymphoma patients in order to learn more about the genetic abnormalities that cause these tumors to develop.  This SCOR brings together leading basic scientists and clinical investigators with complementary expertise in genetics, mouse tumor models, lymphoma cell biology, immunology, drug development and clinical investigation.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.